Corvus Pharmaceuticals (CRVS) Change in Accured Expenses (2015 - 2026)

Corvus Pharmaceuticals' Change in Accured Expenses history runs 12 years deep, the most recent figure standing at $499000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 241.78% year-over-year to $499000.0; the TTM figure through Mar 2026 stood at $3.1 million (up 1657.0% YoY), while the FY2025 annual figure was $2.8 million, up 1226.94% from the prior year.
• Change in Accured Expenses was $499000.0 for Q1 2026 at Corvus Pharmaceuticals, down from $765000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.2 million in Q3 2022 to a low of -$1.9 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$5647.1 across 5 years, with a median of $101000.0 in 2024.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses tumbled 481.53% in 2022, then jumped 895.51% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at -$1.0 million in 2022, then surged by 42.37% to -$589000.0 in 2023, then grew by 16.81% to -$490000.0 in 2024, then surged by 256.12% to $765000.0 in 2025, then slumped by 34.77% to $499000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $499000.0 (Q1 2026), $765000.0 (Q4 2025), and $708000.0 (Q3 2025), per Business Quant data.